Unlocking targeted GPCR signalling in Precision Metabolic Therapeutics

By activating the β₂-adrenergic receptor through a unique signaling pathway, our technology overcomes receptor desensitization and side effects, unlocking the potential for chronic treatment of metabolic disease.

This activation induces:

• Altered signaling profile -> Leading to systemic effects
• Targeted and Precise -> Avoiding undesirable side-effects.

ATR-258´s effect is durable

ATR-258´s effect does not decrease with time and produces none of the side effects seen with conventional β-adrenergic agonist

• Selectively and precisely generates specific metabolic signals.
• Leading to glucose uptake into skeletal muscle, improving glycemic control.
• Binds to the β₂-receptors found in skeletal muscle, initiating the translocation of GLUT4. This process facilitates the transportation of glucose into the muscle cells,
• Helps to lower blood glucose levels and provide energy to build muscle mass and strenght.
• Activates the receptor in a novel manner, causing selective modulation and an altered signaling profile.

We design and develop novel, patentable molecules that unlock the full therapeutic potential of β₂-adrenoceptor signaling. Our growing compound library enables precise targeting across metabolic disorders and beyond. Through innovative drug discovery, Atrogi holds a GPCR Discovery Platform with over 1,000 proprietary compounds and 40 granted patents.